RELIEF THERAPEUTICS Holding (RLF) AI Stock Analysis

• Market Cap: $27.29M
• Dividend Yield: N/A
• Average Volume (3M): 59.97K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.57
• Revenue Growth: 39.52%
• EPS Growth: 83.79%
• Country: CH
• Employees: 31
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -1.00
• Shares Outstanding: 14,076,317
• 10 Day Avg. Volume: 48,270
• 30 Day Avg. Volume: 59,971
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.15
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.81
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: CHF2.50 ▲(16.28%Upside)

The overall score reflects significant financial challenges due to negative profitability metrics and cash flow issues. Technical indicators provide some stability, but valuation remains weak due to negative earnings. Addressing operational hurdles is crucial for improving the financial outlook.

RELIEF THERAPEUTICS Holding Business Overview & Revenue Model

Company Description

Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.

How the Company Makes Money

RELIEF THERAPEUTICS generates revenue primarily through the licensing and commercialization of its pharmaceutical products. The company engages in strategic partnerships and collaborations with other biotech firms, research institutions, and healthcare providers to advance its product pipeline and expand market reach. Revenue streams include milestone payments and royalties from licensing agreements, sales of approved therapies, and potential government grants or subsidies for research and development in the healthcare sector. Additionally, the company may secure funding through equity financing, allowing it to invest in the continued development and commercialization of its therapeutic offerings.

RELIEF THERAPEUTICS Holding Financial Statement Overview

Summary

Despite revenue growth and a strong equity position, negative net profit, EBIT, EBITDA margins, and free cash flow highlight significant profitability and cash management challenges. The company needs to address operational inefficiencies for financial sustainability.

Income Statement

The company shows some improvement in revenue, with a 39.5% growth from the previous year. Gross profit margin improved to 69.4%, but net profit remains negative, impacting the overall profitability. EBIT and EBITDA margins are negative, indicating operational challenges and inefficiencies.

Balance Sheet

The debt-to-equity ratio is low at 0.06, suggesting limited leverage. However, the return on equity is negative due to continued net losses. The equity ratio is strong at 68.9%, indicating financial stability with a substantial equity base.

Cash Flow

Free cash flow remains negative, but it has improved compared to the previous year. The operating cash flow to net income ratio is less relevant due to negative net income. The company needs to improve cash generation to support operations and growth.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.42M	6.03M	6.08M	3.32M	0.00
Gross Profit	5.84M	4.11M	4.83M	-8.59M	0.00
EBITDA	-16.58M	-108.04M	-49.02M	-32.69M	-6.09M
Net Income	-17.12M	-98.18M	-50.79M	-34.70M	-7.83M
Balance Sheet
Total Assets	53.22M	76.39M	188.80M	251.62M	78.05M
Cash, Cash Equivalents and Short-Term Investments	15.08M	14.56M	19.24M	44.76M	43.15M
Total Debt	2.14M	2.96M	4.34M	4.26M	891.00K
Total Liabilities	16.56M	24.16M	43.38M	70.09M	11.00M
Stockholders Equity	36.66M	52.23M	145.42M	181.53M	67.04M
Cash Flow
Free Cash Flow	-3.09M	-18.06M	-24.63M	-49.42M	-18.23M
Operating Cash Flow	-2.92M	-17.61M	-24.11M	-35.71M	-18.23M
Investing Cash Flow	4.40M	8.70M	-8.02M	-30.27M	3.00M
Financing Cash Flow	-862.00K	4.05M	6.42M	67.69M	58.18M

RELIEF THERAPEUTICS Holding Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:RLF, the sentiment is Negative. The current price of 2.15 is below the 20-day moving average (MA) of 2.24, below the 50-day MA of 2.32, and below the 200-day MA of 3.46, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 42.81 is Neutral, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:RLF.

RELIEF THERAPEUTICS Holding Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RLF	50 Neutral	$27.29M	―	-38.10%	―	39.52%	83.79%
Sector *	48 Neutral	AU$2.43B	4.28	-64.25%	2.90%	35.15%	13.63%
MLLCF		$156.05M	―	-40.40%	―	―	―
ELVAF		$10.22M	5.57	16.81%	―	―	―
NWPHF		$169.26M	11.40		―	―	―
SPHDF		$193.16M	2.70	-93.91%	―	―	―
XLS		CHF114.84M	3.23		―	―	―

RELIEF THERAPEUTICS Holding Corporate Events

Relief Therapeutics’ RLF-TD011 Faces Setback with FDA Decision

Relief Therapeutics announced that the FDA did not grant Qualified Infectious Disease Product designation for its investigational therapy RLF-TD011 for epidermolysis bullosa. Despite this, the company maintains its development strategy, supported by Orphan Drug and Rare Pediatric Disease designations, which offer regulatory and commercial incentives. The company continues to progress with the FDA on advancing RLF-TD011 into later-stage development, highlighting its commitment to addressing unmet needs in EB care.

Relief Therapeutics Secures Strong Shareholder Support at AGM

Relief Therapeutics announced that all proposals were approved by a large majority at its annual general meeting, with over 85% of votes in favor. Key resolutions included the approval of the 2024 annual report, re-election of board members, and approval of compensation for the board and executive committee. These approvals reflect strong shareholder support and are likely to bolster the company’s governance and strategic direction.

Relief Therapeutics Secures FDA Rare Pediatric Disease Designation for RLF-TD011

Relief Therapeutics has received the FDA’s Rare Pediatric Disease designation for its product RLF-TD011, aimed at treating epidermolysis bullosa (EB), a rare genetic skin disorder. This designation highlights the potential of RLF-TD011 to advance EB wound care by offering a novel treatment option that modulates the wound microbiome and reduces pathogenic colonization. The designation may also allow Relief to receive a Priority Review Voucher, which could expedite FDA review for future marketing applications, potentially enhancing the company’s market position and offering significant benefits to stakeholders.

Relief Therapeutics Announces 2025 AGM Agenda

Relief Therapeutics has announced the agenda for its 2025 Annual General Meeting, scheduled for June 12, 2025, in Geneva. The agenda includes the approval of the 2024 annual report, financial statements, and compensation amounts for the board and executive committee, among other items. This meeting is crucial for stakeholders as it outlines the company’s governance and financial strategies for the coming year, which could impact its market positioning and operational focus.

Relief Therapeutics Strengthens Financial Position and Advances Pipeline in 2024

Relief Therapeutics has released its 2024 financial results and corporate update, highlighting significant operational achievements and a stronger financial position. The company has made progress in its core pipeline, particularly with its next-generation liquid sapropterin formulation for phenylketonuria and a proprietary hypochlorous acid solution for epidermolysis bullosa. Relief looks forward to achieving important clinical and regulatory milestones in 2025, which could enhance its industry positioning and stakeholder value.